Objective
This study aims to assess the medium-term outcomes of UpholdTM-LITE system for treatment of advanced pelvic organ prolapse (POP).
Methods
This is a retrospective case series of 53 months follow-up of 123 consecutive patients who underwent UpholdTM-LITE system. Objective outcome measure was the anatomical correction of prolapse with POP-Q ≤ Stage 1. Subjective outcome was patient’s feedback to questions 2 and 3 of POPDI-6. Secondary outcome measures the quality of life, presence of lower urinary tract symptoms and complications. Quality of life is assessed by validated questionnaires on UDI-6, IIQ-7, POPDI-6, and PISQ-12 at 1 and 3 years post-operatively.
Results
Objective outcome at 1 and 3 years was at 96.7% and 95.4% respectively. The subjective cure was 95.1% and 91.6%. Five-year cumulative cure rate maintained at 87.2%. Secondary outcomes observed improvement on UDI-6, IIQ-7, POPDI-6 and PISQ-12 postoperatively. Bladder outlet obstruction (BOO) improved while De novo urodynamic stress incontinence (USI) increased slightly post surgically. Mesh erosion rate was 0.8%.
Conclusion
The UpholdTM-LITE system demonstrated good medium term anatomical correction of apical and anterior prolapse, with good subjective cure and improved quality of life. Whilst complication rate was low, a slight increased in De novo USI was observed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.